Category

Cholesterol

Learn more about lipids and lipoproteins, including cholesterol, triglycerides, phospholipids, and lipoproteins.

Cholesterol

#129 – Tom Dayspring, M.D.: The latest insights into cardiovascular disease and lipidology

Atherogenic lipoproteins are really the issue behind clinical atherosclerotic vascular disease. … The data has just become so overwhelming.” —Tom Dayspring

Cholesterol

#24 – Tom Dayspring, M.D., FACP, FNLA – Part V of V: Lp(a), inflammation, oxLDL, remnants, and more

“Use the correct terminology with everything.” –Tom Dayspring

Cholesterol

#23 – Tom Dayspring, M.D., FACP, FNLA – Part IV of V: statins, ezetimibe, PCSK9 inhibitors, niacin, cholesterol and the brain

“This is what it ultimately comes down to – and it’s the way you practice – you’ve got to individualize everything.” –Tom Dayspring

Cholesterol

#22 – Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins

“Here’s something that’s going to shock you: in an average person, anywhere from 30 to 60 percent of the cholesterol in that LDL particle arrived via an HDL particle.” –Tom Dayspring

Cholesterol

#21 – Tom Dayspring, M.D., FACP, FNLA – Part II of V: Lipid metrics, lipid measurements, and cholesterol regulation

“If you learn nothing else today, the first thing is, lipids, for the most part, go nowhere in the human body unless they’re a passenger inside a lipoprotein.” –Tom Dayspring

Cholesterol

#20 – Tom Dayspring, M.D., FACP, FNLA – Part I of V: an introduction to lipidology

“Illustrating things made me understand . . .  I just learned by illustrating.” –Tom Dayspring

Cholesterol

Narrative glossary: lipids

A companion post for the podcast episodes with Thomas Dayspring, M.D., FACP, FNLA (October 15-19, 2018).

Cholesterol

#19 – Dave Feldman: stress testing the lipid energy model

“I am on a journey of science, not of advocacy: I’m going to be quite a skeptic.”  —Dave Feldman

Cholesterol

Transcript — The Drive — Dave Feldman

Transcript of episode 19 of The Drive with Peter Attia, released October 8, 2018.

Cholesterol

Statins, Lp(a), and upcoming podcast guests

In other words, statins are not addressing the associated risk in patients with an elevated Lp(a), and this population represents about 25% of those with previous CVD or an indication for statins.

Facebook icon Twitter icon Instagram icon Pinterest icon Google+ icon YouTube icon LinkedIn icon Contact icon